Nsaids and increased blood pressure: What is the clinical significance?
Several randomised studies have demonstrated that various nonsteroidal anti-inflammatory drugs (NSAIDs) elevate blood pressure in normotensive and hypertensive individuals; however, these data have been contradicted by numerous negative studies. Two meta-analyses have demonstrated that, after poolin...
Gespeichert in:
Veröffentlicht in: | Drug safety 1997-11, Vol.17 (5), p.277-289 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 289 |
---|---|
container_issue | 5 |
container_start_page | 277 |
container_title | Drug safety |
container_volume | 17 |
creator | JOHNSON, A. G |
description | Several randomised studies have demonstrated that various nonsteroidal anti-inflammatory drugs (NSAIDs) elevate blood pressure in normotensive and hypertensive individuals; however, these data have been contradicted by numerous negative studies. Two meta-analyses have demonstrated that, after pooling data drawn from published reports of randomised trials of younger adults, NSAID use produces a clinically significant increment in mean blood pressure of 5 mm Hg, most marked in patients with controlled hypertension. Stratification by NSAID type revealed that piroxicam, naproxen and indomethacin had the greatest, and sulindac the smallest, pressor effect. These data were supported by 2 large community studies involving elderly patients. Recent NSAID users had a 1.7-fold higher risk of requiring the initiation of antihypertensive therapy compared with nonusers; NSAID users also had a 40% increased risk of receiving a diagnosis of hypertension compared with nonusers. It is vital to determine the nature of the association in the elderly, 12 to 15% of whom are concurrently receiving an NSAID and an antihypertensive agent. Importantly, a 5 to 6 mm Hg increase in diastolic blood pressure maintained over a few years may be associated with a 67% increase in total stroke risk and a 15% increase in coronary heart disease events. While the mechanism(s) remain speculative, salt and water retention through several factors operating in parallel, coupled with increased total peripheral vascular resistance, via increased renal endothelin-1 synthesis, are potentially important. Clinicians should strive to avoid excessive use of NSAID treatment and consider well-tolerated therapeutic alternatives, including simple analgesics and physical therapy. For patients who require concomitant NSAID and antihypertensive treatment, physicians should be aware that indomethacin, naproxen and piroxicam may be associated with a greater pressor effect than many other NSAIDs, and that antagonism of beta-blockers may be greater than that of vasodilators (including ACE inhibitors and calcium antagonists) and diuretics. Finally, the progress of each patient should be monitored by careful blood pressure measurement, particularly during the period of initiation of NSAID therapy. |
doi_str_mv | 10.2165/00002018-199717050-00001 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17279070</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17279070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-679a1327e91735e80ebf30ddd866052b04071a44fc8396259a305c678dd17c433</originalsourceid><addsrcrecordid>eNo9kMFOwzAMhnMAjTF4BKQcELdCnLRJwwWhCQbSBBcQxypNUhbUtSNuD7w9GRvzxdbv37b8EUKBXXOQxQ1LwRmUGWitQLGCZVsJjsiUAeRZoUGekFPEr6SWXJYTMtFCg1J8ShYvaIJDajpHQ2ejN-gdrdu-d3QTPeIY_S39WJmBBqTDylPbhi5Y01IMn11oUtlZf3dGjhvToj_f5xl5f3x4mz9ly9fF8_x-mVkBxZBJpQ0Irnw6LwpfMl83gjnnSilZwWuWMwUmzxtbCi15oY1ghZWqdA6UzYWYkavd3k3sv0ePQ7UOaH3bms73I1aguNJMsWQsd0Ybe8Tom2oTw9rEnwpYteVW_XOrDtz-JEijF_sbY7327jC4h5b6l_u-wQSiiYlAwIONp0ekFOIXmnx1QQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17279070</pqid></control><display><type>article</type><title>Nsaids and increased blood pressure: What is the clinical significance?</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>JOHNSON, A. G</creator><creatorcontrib>JOHNSON, A. G</creatorcontrib><description>Several randomised studies have demonstrated that various nonsteroidal anti-inflammatory drugs (NSAIDs) elevate blood pressure in normotensive and hypertensive individuals; however, these data have been contradicted by numerous negative studies. Two meta-analyses have demonstrated that, after pooling data drawn from published reports of randomised trials of younger adults, NSAID use produces a clinically significant increment in mean blood pressure of 5 mm Hg, most marked in patients with controlled hypertension. Stratification by NSAID type revealed that piroxicam, naproxen and indomethacin had the greatest, and sulindac the smallest, pressor effect. These data were supported by 2 large community studies involving elderly patients. Recent NSAID users had a 1.7-fold higher risk of requiring the initiation of antihypertensive therapy compared with nonusers; NSAID users also had a 40% increased risk of receiving a diagnosis of hypertension compared with nonusers. It is vital to determine the nature of the association in the elderly, 12 to 15% of whom are concurrently receiving an NSAID and an antihypertensive agent. Importantly, a 5 to 6 mm Hg increase in diastolic blood pressure maintained over a few years may be associated with a 67% increase in total stroke risk and a 15% increase in coronary heart disease events. While the mechanism(s) remain speculative, salt and water retention through several factors operating in parallel, coupled with increased total peripheral vascular resistance, via increased renal endothelin-1 synthesis, are potentially important. Clinicians should strive to avoid excessive use of NSAID treatment and consider well-tolerated therapeutic alternatives, including simple analgesics and physical therapy. For patients who require concomitant NSAID and antihypertensive treatment, physicians should be aware that indomethacin, naproxen and piroxicam may be associated with a greater pressor effect than many other NSAIDs, and that antagonism of beta-blockers may be greater than that of vasodilators (including ACE inhibitors and calcium antagonists) and diuretics. Finally, the progress of each patient should be monitored by careful blood pressure measurement, particularly during the period of initiation of NSAID therapy.</description><identifier>ISSN: 0114-5916</identifier><identifier>DOI: 10.2165/00002018-199717050-00001</identifier><identifier>PMID: 9391772</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Adult ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Biological and medical sciences ; Blood Pressure - drug effects ; Drug toxicity and drugs side effects treatment ; Humans ; Hypertension - chemically induced ; Hypertension - epidemiology ; Hypertension - pathology ; Medical sciences ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Toxicity: cardiovascular system</subject><ispartof>Drug safety, 1997-11, Vol.17 (5), p.277-289</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2052663$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9391772$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JOHNSON, A. G</creatorcontrib><title>Nsaids and increased blood pressure: What is the clinical significance?</title><title>Drug safety</title><addtitle>Drug Saf</addtitle><description>Several randomised studies have demonstrated that various nonsteroidal anti-inflammatory drugs (NSAIDs) elevate blood pressure in normotensive and hypertensive individuals; however, these data have been contradicted by numerous negative studies. Two meta-analyses have demonstrated that, after pooling data drawn from published reports of randomised trials of younger adults, NSAID use produces a clinically significant increment in mean blood pressure of 5 mm Hg, most marked in patients with controlled hypertension. Stratification by NSAID type revealed that piroxicam, naproxen and indomethacin had the greatest, and sulindac the smallest, pressor effect. These data were supported by 2 large community studies involving elderly patients. Recent NSAID users had a 1.7-fold higher risk of requiring the initiation of antihypertensive therapy compared with nonusers; NSAID users also had a 40% increased risk of receiving a diagnosis of hypertension compared with nonusers. It is vital to determine the nature of the association in the elderly, 12 to 15% of whom are concurrently receiving an NSAID and an antihypertensive agent. Importantly, a 5 to 6 mm Hg increase in diastolic blood pressure maintained over a few years may be associated with a 67% increase in total stroke risk and a 15% increase in coronary heart disease events. While the mechanism(s) remain speculative, salt and water retention through several factors operating in parallel, coupled with increased total peripheral vascular resistance, via increased renal endothelin-1 synthesis, are potentially important. Clinicians should strive to avoid excessive use of NSAID treatment and consider well-tolerated therapeutic alternatives, including simple analgesics and physical therapy. For patients who require concomitant NSAID and antihypertensive treatment, physicians should be aware that indomethacin, naproxen and piroxicam may be associated with a greater pressor effect than many other NSAIDs, and that antagonism of beta-blockers may be greater than that of vasodilators (including ACE inhibitors and calcium antagonists) and diuretics. Finally, the progress of each patient should be monitored by careful blood pressure measurement, particularly during the period of initiation of NSAID therapy.</description><subject>Adult</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Humans</subject><subject>Hypertension - chemically induced</subject><subject>Hypertension - epidemiology</subject><subject>Hypertension - pathology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Toxicity: cardiovascular system</subject><issn>0114-5916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMFOwzAMhnMAjTF4BKQcELdCnLRJwwWhCQbSBBcQxypNUhbUtSNuD7w9GRvzxdbv37b8EUKBXXOQxQ1LwRmUGWitQLGCZVsJjsiUAeRZoUGekFPEr6SWXJYTMtFCg1J8ShYvaIJDajpHQ2ejN-gdrdu-d3QTPeIY_S39WJmBBqTDylPbhi5Y01IMn11oUtlZf3dGjhvToj_f5xl5f3x4mz9ly9fF8_x-mVkBxZBJpQ0Irnw6LwpfMl83gjnnSilZwWuWMwUmzxtbCi15oY1ghZWqdA6UzYWYkavd3k3sv0ePQ7UOaH3bms73I1aguNJMsWQsd0Ybe8Tom2oTw9rEnwpYteVW_XOrDtz-JEijF_sbY7327jC4h5b6l_u-wQSiiYlAwIONp0ekFOIXmnx1QQ</recordid><startdate>19971101</startdate><enddate>19971101</enddate><creator>JOHNSON, A. G</creator><general>Adis international</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U2</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>19971101</creationdate><title>Nsaids and increased blood pressure: What is the clinical significance?</title><author>JOHNSON, A. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-679a1327e91735e80ebf30ddd866052b04071a44fc8396259a305c678dd17c433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Humans</topic><topic>Hypertension - chemically induced</topic><topic>Hypertension - epidemiology</topic><topic>Hypertension - pathology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Toxicity: cardiovascular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JOHNSON, A. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JOHNSON, A. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nsaids and increased blood pressure: What is the clinical significance?</atitle><jtitle>Drug safety</jtitle><addtitle>Drug Saf</addtitle><date>1997-11-01</date><risdate>1997</risdate><volume>17</volume><issue>5</issue><spage>277</spage><epage>289</epage><pages>277-289</pages><issn>0114-5916</issn><abstract>Several randomised studies have demonstrated that various nonsteroidal anti-inflammatory drugs (NSAIDs) elevate blood pressure in normotensive and hypertensive individuals; however, these data have been contradicted by numerous negative studies. Two meta-analyses have demonstrated that, after pooling data drawn from published reports of randomised trials of younger adults, NSAID use produces a clinically significant increment in mean blood pressure of 5 mm Hg, most marked in patients with controlled hypertension. Stratification by NSAID type revealed that piroxicam, naproxen and indomethacin had the greatest, and sulindac the smallest, pressor effect. These data were supported by 2 large community studies involving elderly patients. Recent NSAID users had a 1.7-fold higher risk of requiring the initiation of antihypertensive therapy compared with nonusers; NSAID users also had a 40% increased risk of receiving a diagnosis of hypertension compared with nonusers. It is vital to determine the nature of the association in the elderly, 12 to 15% of whom are concurrently receiving an NSAID and an antihypertensive agent. Importantly, a 5 to 6 mm Hg increase in diastolic blood pressure maintained over a few years may be associated with a 67% increase in total stroke risk and a 15% increase in coronary heart disease events. While the mechanism(s) remain speculative, salt and water retention through several factors operating in parallel, coupled with increased total peripheral vascular resistance, via increased renal endothelin-1 synthesis, are potentially important. Clinicians should strive to avoid excessive use of NSAID treatment and consider well-tolerated therapeutic alternatives, including simple analgesics and physical therapy. For patients who require concomitant NSAID and antihypertensive treatment, physicians should be aware that indomethacin, naproxen and piroxicam may be associated with a greater pressor effect than many other NSAIDs, and that antagonism of beta-blockers may be greater than that of vasodilators (including ACE inhibitors and calcium antagonists) and diuretics. Finally, the progress of each patient should be monitored by careful blood pressure measurement, particularly during the period of initiation of NSAID therapy.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>9391772</pmid><doi>10.2165/00002018-199717050-00001</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0114-5916 |
ispartof | Drug safety, 1997-11, Vol.17 (5), p.277-289 |
issn | 0114-5916 |
language | eng |
recordid | cdi_proquest_miscellaneous_17279070 |
source | MEDLINE; SpringerNature Journals |
subjects | Adult Anti-Inflammatory Agents, Non-Steroidal - adverse effects Biological and medical sciences Blood Pressure - drug effects Drug toxicity and drugs side effects treatment Humans Hypertension - chemically induced Hypertension - epidemiology Hypertension - pathology Medical sciences Pharmacology. Drug treatments Randomized Controlled Trials as Topic Toxicity: cardiovascular system |
title | Nsaids and increased blood pressure: What is the clinical significance? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T04%3A02%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nsaids%20and%20increased%20blood%20pressure:%20What%20is%20the%20clinical%20significance?&rft.jtitle=Drug%20safety&rft.au=JOHNSON,%20A.%20G&rft.date=1997-11-01&rft.volume=17&rft.issue=5&rft.spage=277&rft.epage=289&rft.pages=277-289&rft.issn=0114-5916&rft_id=info:doi/10.2165/00002018-199717050-00001&rft_dat=%3Cproquest_cross%3E17279070%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17279070&rft_id=info:pmid/9391772&rfr_iscdi=true |